A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Takahiro Fukuhara, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yosuke Takeda, Yuko Tsuge, Takeki Uehara
doi: https://doi.org/10.1101/2022.05.17.22275027

Data Availability

Shionogi & Co., Ltd. is committed to disclosing the synopses and results of its clinical trials and sharing clinical trial data with researchers on reasonable request. For further details, please refer to the websites of Shionogi & Co., Ltd. (https://www.shionogi.com/shionogi/global/en/company/policies/shionogi-group-clinical-trial-data-transparency-policy.html) and Vivli (https://vivli.org/).

Back to top
Posted May 17, 2022.
Download PDF

Supplementary Material

Data/Code
Email
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Takahiro Fukuhara, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yosuke Takeda, Yuko Tsuge, Takeki Uehara
medRxiv 2022.05.17.22275027; doi: https://doi.org/10.1101/2022.05.17.22275027
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area